Insmed(INSM) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —TPIP Program Advancing with Phase 3 Studies Planned to Begin for PH-ILD in the Second Half of 2025 and for PAH in Early 2 ...